去势抵抗性前列腺癌(CRPC)的形成机制及其免疫治疗研究进展  

Formation mechanism and research progress on the immunotherapy of castrate-resistant prostate cancer(CRPC)

作　　者：邱衍怡 周晓辉[1] QIU Yanyi;ZHOU Xiaohui(China Pharmaceutical University,Nanjing 211198,China)

机构地区：[1]中国药科大学,江苏南京211198

出　　处：《药学研究》2024年第7期671-676,共6页Journal of Pharmaceutical Research

基　　金：国家自然科学基金项目(No.82070781)。

摘　　要：前列腺癌(prostate cancer,PCa)是困扰全球男性的恶性生殖系统疾病,疾病起始阶段对雄激素剥夺疗法(ADT)表现出良好应答。然而,患者不可避免地出现激素抵抗,从而进展为去势抵抗性前列腺癌(CRPC),极大降低患者生存率。临床上对CRPC研究主要围绕雄激素受体(AR)展开,此外也存在AR旁路途径。本综述将围绕雄激素受体依赖与旁路两种途径,讨论CRPC的形成机制,以及针对CRPC患者的免疫治疗方案的研究进展。Prostate cancer(PCa)is a malignant reproductive disease that afflicts men worldwide,with a favourable response to androgen deprivation therapy(ADT)in the initial stages of the disease.However,patients inevitably develop hormonal resistance,which progresses to castrate-resistant prostate cancer(CRPC)and greatly reduces patient survival.Clinical studies of CRPC are mainly centred around the androgen receptor(AR),but AR bypass pathways also exist.Therefore,this review discussed the formation mechanism of CRPC and the progress of immunotherapeutic regimens for patients with CRPC,focusing on both androgen receptor-dependent and bypass pathways.

关 键 词：去势抵抗性前列腺癌 形成机制 雄激素受体 免疫疗法 

分 类 号：R737.25[医药卫生—肿瘤]